Clinical Trial: Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Child
Brief Summary: Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
Detailed Summary:
Sponsor: Novartis Vaccines
Current Primary Outcome: Persistence of memory B cells in the blood at least one year after primary immunisation with MenC Vaccine at 2, 3 and 4 months of age, as determined by meningococcal C specific B-cell ELISPot assay or limiting dilution
Original Primary Outcome:
Current Secondary Outcome:
- Immune Response measured 4 weeks after the booster immunisation.
- establish at which day CRM -197 specific B cells are detectable in the blood after booster immunisation, as determined by meningococcal C specific B-cell ELISpot assay or limiting dilution.
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: April 3, 2006
Date Started: April 2006
Date Completion:
Last Updated: September 18, 2014
Last Verified: September 2014
